This site is intended for healthcare professionals
The short-acting bronchodilator orciprenaline sulphate (Alupent) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA.
It concluded that the adverse events associated with the drug outweigh its clinical benefits.
Patients who are currently receiving Alupent should be switched to a more selective ß2-agonist, such as salbutamol or terbutaline, as soon as possible.
The most up-to-date drug information at your fingertips.
EXCLUSIVE TO SUBSCRIBERS See the latest products removed...
EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...
A National Patient Safety Alert (NatPSA) has been issued...
EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...
Drugs
Conditions
News and resources
MIMS Supported Resources